Meanwhile, aromatic sulfonamide compounds did not affect the growth of BXD-3752 glioma cells without IDH1 mutation, which indicates that aromatic sulfonamide compounds will have a higher selectivity for IDH1 mutated glioma cells. This evidence concerns the gene IDH1 and central nervous system cancer.